Current thinking on the developments shaping private company decision-making in Australia and across the United States cross-border corridor.
ASIC's fast-track IPO trial has changed the economics of going public. The private capital markets landscape has also shifted. For most private company boards, the calculation that held in 2022 no longer applies.
Read the article →The circumstances in which the Takeovers Panel orders costs, what the Emu NL decision signals for future applicants, and the principles driving the outcome.
How the refundable and non-refundable components of the research and development tax incentive apply to clinical-stage life sciences companies.
How boards should compare the two most common exit structures on value, speed, and post-exit involvement.
The specific provisions a shareholder agreement needs if a company is considering a public listing within three years.
Common structuring issues for family trusts holding operating businesses, and when restructure is warranted.
What United States defence and life sciences acquirers need to understand about Foreign Investment Review Board approvals.
The commercial triggers that should prompt a private company board to appoint an independent director.
Choosing the right early-stage capital structure in the Australian market.
The transactions in which warranty and indemnity insurance is worth the premium, and where it is not.